Regeneron Pharmaceuticals, Inc.'s (REGN) CEO Leonard Schleifer on Q2 2022 Results - Earnings Call Transcript

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET

Company Participants

Ryan Crowe - Vice President, Investor Relations

Leonard Schleifer - President, Chief Executive Officer

George Yancopoulos - President, Chief Scientific Officer

Marion McCourt - Executive Vice President, Head of Commercial

Robert Landry - Executive Vice President, Chief Financial Officer

Conference Call Participants

Mohit Bansal - Wells Fargo

Evan Seigerman - BMO Capital Markets

Tyler Van Buren - Cowen

Salveen Richter - Goldman Sachs

Matthew Harrison - Morgan Stanley

Tim Anderson - Wolfe Research

Chris Raymond - Piper Sandler

Carter Gould - Barclays Capital

Operator

Welcome to the Regeneron Pharmaceuticals Second Quarter 2022 Earnings Conference Call. My name is Bella and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that today’s conference is being recorded.

I will now turn the call over to Ryan Crowe, Vice President, Investor Relations. You may begin.

Ryan Crowe

Thank you, Bella. Good morning, good afternoon and good evening to everyone listening around the globe. Thank you for your interest in Regeneron and welcome to our second quarter 2022 earnings conference call. An archive of this webcast will be available on our Investor Relations website shortly after the call ends.

Joining me today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Financial Officer. After our prepared remarks, we will open the call for Q&A.

I would also like to remind you that remarks made on this call today include forward-looking statements about Regeneron. Such statements may include but are not limited to those related to Regeneron and its products and businesses, financial forecasts and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payor coverage and reimbursement issues, intellectual property, pending litigation, and other proceedings and competition.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other materials risks can be found in Regeneron’s filings with the United States Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended June 30, 2022 which was filed with the SEC this morning. Regeneron does not undertake any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise.